Table 3. Relationships between intratumoral/peritumoral CD68 expression and clinicopathologic features.

Variables	Intratumoral CD68 expression		Peritumoral CD68 expression
	Average level or correlation coefficient*	P	Average level or correlation coefficient*	P
Age	0.148	0.011	−0.029	0.623
Gender, male vs. female	0.012±0.025 vs. 0.008±0.010	0.297	0.020±0.018 vs. 0.021±0.028	0.733
Hepatitis B history, yes vs. no	0.012±0.024 vs. 0.010±0.023	0.590	0.020±0.021 vs. 0.021±0.017	0.503
Hepatitis B e antigen, positive vs. negative	0.011±0.026 vs. 0.012±0.022	0.822	0.021±0.024 vs. 0.019±0.018	0.449
ALT	0.013	0.825	−0.013	0.823
AST	0.091	0.120	0.118	0.045
γ-GT	0.036	0.542	0.126	0.031
ALP	0.079	0.178	0.092	0.116
Liver cirrhosis, yes vs. no	0.012±0.026 vs. 0.008±0.010	0.225	0.021±0. 018 vs. 0.017±.0.025	0.123
α-Fetoprotein	0.062	0.285	0.183	0.002
Tumor size	0.039	0.505	0.389	<0.001
Tumor encapsulation,complete vs. no	0.012±0.025 vs. 0.011±0.022	0.683	0.018±0.016 vs. 0.022±0.023	0.093
Microvascular invasion, yes vs. no	0.014±0.029 vs. 0.010±0.019	0.192	0.024±0.025 vs. 0.017±0.015	0.005
Tumor differentiation, I–II vs.III–IV	0.009±0.014 vs. 0.016±0.037	0.103	0.020±0.018 vs. 0.020±0.025	0.745
TNM stage, I vs. II/IIIA	0.010±0.020 vs. 0.013±0.027	0.309	0.017±0.015 vs. 0.024±0.024	0.004

^*If the clinicopathologic variable is a quantitative one, Spearman’s correlation analysis was performed and the correlation coefficient was presented.

Abbreviations: y, year; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ-GT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase.